Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olorinab in Irritable Bowel Syndrome (CAPTIVATE)
NCT04043455Phase 2Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olorinab in irritable bowel syndrome (IBS), sponsored by Arena Pharmaceuticals, Inc.. Started Jul 2019; status: terminated.
02
Drugs
olorinab
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT04043455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04043455.